Pfizer Inc
$ 25.57
1.67%
03 Dec - close price
- Market Cap 145,383,539,000 USD
- Current Price $ 25.57
- High / Low $ 25.89 / 25.30
- Stock P/E 14.87
- Book Value 16.32
- EPS 1.72
- Next Earning Report 2026-02-03
- Dividend Per Share $1.70
- Dividend Yield 6.76 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.11 %
- 52 Week High 27.21
- 52 Week Low 19.83
About
Pfizer Inc. is a preeminent global pharmaceutical and biotechnology firm based in New York City, with a storied legacy of innovation since its founding in 1849. The company is renowned for its diverse therapeutic portfolio, which spans immunology, oncology, and cardiology, and is supported by a robust pipeline of groundbreaking treatments. Notably, Pfizer's rapid development of the COVID-19 vaccine underscored its agility in research and commitment to addressing urgent public health needs. Through strategic collaborations and ongoing investment in cutting-edge research, Pfizer is poised to sustain its leadership position in the healthcare sector while continuing to improve health outcomes worldwide.
Analyst Target Price
$29.04
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-05 | 2025-04-29 | 2025-02-04 | 2024-10-29 | 2024-07-30 | 2024-05-01 | 2024-01-30 | 2023-10-31 | 2023-08-01 | 2023-05-02 | 2023-01-31 |
| Reported EPS | 0.87 | 0.78 | 0.92 | 0.63 | 1.06 | 0.6 | 0.82 | 0.1 | -0.17 | 0.67 | 1.23 | 1.14 |
| Estimated EPS | 0.63 | 0.57 | 0.67 | 0.46 | 0.61 | 0.46 | 0.51 | -0.18 | -0.34 | 0.58 | 0.99 | 1.04 |
| Surprise | 0.24 | 0.21 | 0.25 | 0.17 | 0.45 | 0.14 | 0.31 | 0.28 | 0.17 | 0.09 | 0.24 | 0.1 |
| Surprise Percentage | 38.0952% | 36.8421% | 37.3134% | 36.9565% | 73.7705% | 30.4348% | 60.7843% | 155.5556% | 50% | 15.5172% | 24.2424% | 9.6154% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.6 |
| Currency | USD |
Previous Dividend Records
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2025-12-01 | 2025-09-02 | 2025-06-13 | 2025-03-07 | 2024-12-02 | 2024-09-03 | 2024-06-14 | 2024-03-01 | 2023-12-04 | 2023-09-05 |
| Amount | $0.43 | $0.43 | $0.43 | $0.43 | $0.42 | $0.42 | $0.42 | $0.42 | $0.41 | $0.41 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PFE
2025-12-04 13:03:08
Pfizer is projected to see its shares trade for $33.60 by the end of 2025 and $34.08 by 2030, representing potential upsides of 31.40% and 33.28% respectively. The company is pivoting from its COVID-dependent revenue to focus on oncology, obesity drugs, and co-marketed products, aiming for margin expansion and growth in these lucrative areas. Despite recent struggles and a significant drop from its 2021 peak, analysts maintain a "Hold" rating, with some seeing a promising future due to strategic shifts and pipeline developments.
2025-12-04 12:15:08
The global pharmacy market is projected to reach $3.4 trillion by 2035, growing at a 7.6% CAGR, driven by expanding healthcare systems, increased chronic disease prevalence, and digital health advancements. North America is expected to dominate, while Asia Pacific will be the fastest-evolving region. Key trends include the acceleration of digital pharmacy, the rise of specialty pharmacies, and the expansion of pharmacist-led clinical services.
2025-12-04 12:05:00
Jim Cramer recommends holding onto Pfizer (NYSE: PFE) despite its recent share price stagnation, viewing it as a bond equivalent due to its high dividend yield. He believes the company's acquisitions, like Seagen and Metsera (for GLP-1 weight loss drugs), will help build a strong pipeline to offset patent expirations and drive future growth. Cramer sees potential for a breakout, expecting Dr. Bourla to outline growth plans at the upcoming JPMorgan conference.
2025-12-04 01:29:27
Pfizer and Astellas secured FDA approval for PADCEV/Keytruda as a perioperative treatment for cisplatin-ineligible muscle-invasive bladder cancer, enhancing Pfizer’s oncology portfolio. This approval strengthens Pfizer's oncology investment narrative, though overall expectations for the company remain balanced due to upcoming patent expirations, pricing pressures, and high debt. Despite this win, investors also weigh Metsera acquisition, cost-cutting, and elevated dividends against earnings dilution and leverage.
2025-12-04 00:05:00
Jim Cramer recommends holding Pfizer (PFE), citing its growth potential in 2026 and its attractive 6.8% yield. He believes Pfizer's acquisitions, including Seagen and NURTEC, will strengthen its pipeline and help it overcome patent expirations and generate future growth, despite concerns from some investors. Cramer views Pfizer as a "bond equivalent" due to its high yield and potential turnaround.
2025-12-03 22:35:58
Amgen (NASDAQ: AMGN) reached a new 52-week high of $345.95 on December 3, 2025, driven by strong Q3 earnings, the promising obesity drug MariTide, and analyst upgrades. While the stock's year-to-date gain is over 34%, analysts express caution due to valuation concerns and upcoming patent expirations, balancing the optimism around its pipeline and diversified growth. The future performance heavily relies on MariTide's clinical trial outcomes and the company's ability to navigate competitive and regulatory pressures.
